Sobi-Invitation to Conference Call today at 2.30 pm CET
Financial analysts and media are invited to a telephone conference today at
2.30 p.m. CET following the joint release with Biogen Idec of the top-line
results from the phase 3 study investigating long-lasting recombinant factor IX
fusion protein in Hemophilia B. The call will be hosted by CEO Geoffrey
McDonough.
Slides used in the presentation will be available on www.sobi.com prior to the
telephone conference.
Details for participation
Please call:
Sweden: +46 (0)8 505 598 45
UK: +44 (0)207 108 63 03
US: +1 866Â 676 58 69
Yours sincerely,
Ã…sa Stenqvist,
VP Communications and IR (Interim)
Phone: +46 8 697 21 88
Swedish Orphan Biovitrum (Sobi)
Sobi is an international healthcare company dedicated to bringing innovative
therapies and services to improve the lives of rare disease patients. The
product portfolio is primarily focused on Inflammation and Genetic diseases,
with three late stage biological development projects within hemophilia and
neonatology. Sobi also markets more than 40 products for companies in the
specialty and rare disease space. In 2011, Sobi had revenues of SEK 1.9 billion
and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.
Invitation TC September 26, 2012 in pdf format:
http://hugin.info/134557/R/1643713/529470.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1643713]
